Changes in intensity of pain (VAS 0 to 10) tested through tactile stimuli · Patients aged above 12 years with self-reported tooth hypersensitivity confirmed on clinical evaluation
Er,Cr:YSGG laser (erbium,chromium:yttrium-scandium-gallium-garnet) showed no clear difference in changes in intensity of pain (VAS 0 to 10) tested through tactile… compared with placebo (placebo laser or placebo agent) or no treatment; GRADE not reported.
1 finding from 1 review
50% responder rate · people with focal epilepsy
Zonisamide probably leads to higher 50% responder rate (whole treatment period; any dose) compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawal rates ‐ Any dose · people with focal epilepsy
Zonisamide probably leads to higher withdrawal rates (whole treatment period; any dose) compared with placebo (moderate certainty).
1 finding from 1 review
Ataxia · people with focal epilepsy
Zonisamide may leads to higher adverse effects: ataxia (whole treatment period; any dose) compared with placebo (low certainty).
1 finding from 1 review
Frequency of adverse effects ‐ dizziness ( · people with focal epilepsy
Zonisamide probably leads to higher adverse effects: dizziness (whole treatment period; any dose) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effect: fatigue · people with focal epilepsy
Zonisamide probably leads to higher adverse effects: fatigue (whole treatment period; any dose) compared with placebo (moderate certainty).
1 finding from 1 review
Nausea · people with focal epilepsy
Zonisamide probably leads to higher adverse effects: nausea (whole treatment period; any dose) compared with placebo (moderate certainty).
1 finding from 1 review
Somnolence · people with focal epilepsy
Zonisamide probably leads to higher adverse effects: somnolence (whole treatment period; any dose) compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · atherosclerotic cardiovascular disease
EDTA showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
Coronary heart disease mortality – CHD deaths · atherosclerotic cardiovascular disease
It is very uncertain whether EDTA changes coronary heart disease death compared with placebo (very low certainty).
1 finding from 1 review
Myocardial infarction · atherosclerotic cardiovascular disease
EDTA showed no clear difference in myocardial infarction compared with placebo (moderate certainty).
1 finding from 1 review
Angina · atherosclerotic cardiovascular disease
It is very uncertain whether EDTA changes angina compared with placebo (very low certainty).
1 finding from 1 review
Stroke · atherosclerotic cardiovascular disease
EDTA showed no clear difference in stroke compared with placebo (low certainty).
1 finding from 1 review
Ankle brachial index · atherosclerotic cardiovascular disease
1 finding from 1 review
Maximum walking distance · atherosclerotic cardiovascular disease
1 finding from 1 review
Cervical dystonia‐specific improvement · cervical dystonia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Adverse events at 4 weeks; 1085 participants (8 RCTs) · cervical dystonia
Botulinum toxin type A probably leads to higher adverse events at 4 weeks; 1085 participants (8 RCTs) compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.23 [1.05, 1.43]
Studies not reported
Moderate
Subjective participant assessment at 4 weeks; 755 participants(6 RCTs) · cervical dystonia
Botulinum toxin type A leads to higher subjective participant assessment at 4 weeks; 755 participants(6 RCTs) compared with placebo (high certainty).
1 finding from 1 review
RR 2.19 [1.78, 2.7]
Studies not reported
High
Cervical dystonia‐specific pain · cervical dystonia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Tolerability assessed as dropouts at 4 to 6 weeks: 705 participants (5 RCTs) · cervical dystonia
Botulinum toxin type A leads to lower tolerability assessed as dropouts at 4 to 6 weeks: 705 participants… compared with placebo (high certainty).
1 finding from 1 review
RR 0.48 [0.32, 0.73]
Studies not reported
High